Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.
Nanobody
Radioiodination
Single domain antibody fragment
Site-specific labeling
VHH
Journal
Nuclear medicine and biology
ISSN: 1872-9614
Titre abrégé: Nucl Med Biol
Pays: United States
ID NLM: 9304420
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
20
04
2020
revised:
06
05
2020
accepted:
07
05
2020
pubmed:
26
5
2020
medline:
5
10
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
As a consequence of their small size, high stability and high affinity, single domain antibody fragments (sdAbs) are appealing targeting vectors for radiopharmaceutical development. With sdAbs binding to internalizing receptors like HER2, residualizing prosthetic agents can enhance tumor retention of radioiodine, which until now has been done with random labeling approaches. Herein we evaluate a site-specific strategy utilizing a radioiodinated, residualizing maleimido moiety and the anti-HER2 sdAb 5F7 bearing a GGC tail for conjugation. Maleimidoethyl 3-(guanidinomethyl)-5-iodobenzoate ([ [ [ The site specific nature of the [
Identifiants
pubmed: 32448731
pii: S0969-8051(20)30115-3
doi: 10.1016/j.nucmedbio.2020.05.002
pmc: PMC7657985
mid: NIHMS1596967
pii:
doi:
Substances chimiques
Iodine Radioisotopes
0
Single-Domain Antibodies
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-183Subventions
Organisme : NCI NIH HHS
ID : R01 CA042324
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA042324
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest G.V. and M.Z are consultants of Cereius, Inc. and hold ownership interest, including patents/patent applications in single domain antibody fragment radiolabeling methods.
Références
Chem Biol. 2013 Feb 21;20(2):161-7
pubmed: 23438745
Cancer Biother Radiopharm. 1996 Apr;11(2):133-44
pubmed: 10851530
FASEB J. 2011 Jul;25(7):2433-46
pubmed: 21478264
J Nucl Med. 2018 Jan;59(1):93-99
pubmed: 28864631
Radiother Oncol. 1984 Dec;2(4):343-66
pubmed: 6097949
J Immunol Methods. 1984 Aug 3;72(1):77-89
pubmed: 6086763
Nat Commun. 2014 Sep 05;5:4740
pubmed: 25190082
Nucl Med Biol. 2015 Jan;42(1):19-27
pubmed: 25240914
Mol Imaging Biol. 2016 Feb;18(1):1-17
pubmed: 26754790
Chemistry. 2019 Jan 2;25(1):43-59
pubmed: 30095185
Bioconjug Chem. 2012 Mar 21;23(3):409-20
pubmed: 22296587
J Med Chem. 2014 Oct 9;57(19):7890-9
pubmed: 25191794
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
J Nucl Med. 2003 Jul;44(7):1148-55
pubmed: 12843231
Nucl Med Biol. 2013 Jan;40(1):52-9
pubmed: 23159171
Drug Discov Today Technol. 2018 Dec;30:91-104
pubmed: 30553525
Int J Rad Appl Instrum B. 1992 Apr;19(3):289-95
pubmed: 1629018
Org Biomol Chem. 2016 Jan 28;14(4):1261-71
pubmed: 26645790
J Med Chem. 1994 Aug 5;37(16):2609-18
pubmed: 8057303
Bioconjug Chem. 2018 Dec 19;29(12):4090-4103
pubmed: 30384599
Nucl Med Biol. 2014 Nov-Dec;41(10):802-12
pubmed: 25156548
Bioconjug Chem. 2006 Jul-Aug;17(4):1085-92
pubmed: 16848419
Bioconjug Chem. 1998 Jan-Feb;9(1):72-86
pubmed: 9460549
J Control Release. 2020 Jan 10;317:34-42
pubmed: 31734445
Nat Protoc. 2007;2(2):282-6
pubmed: 17406587
Clin Cancer Res. 2017 Nov 1;23(21):6616-6628
pubmed: 28751451
Nucl Med Biol. 2009 May;36(4):355-61
pubmed: 19423002
Science. 1989 May 12;244(4905):707-12
pubmed: 2470152
Bioorg Med Chem. 2018 May 1;26(8):1939-1949
pubmed: 29534937
J Nucl Med. 2014 Apr;55(4):650-6
pubmed: 24578241
Free Radic Biol Med. 2013 Dec;65:244-253
pubmed: 23747983
Bioconjug Chem. 2002 Sep-Oct;13(5):985-95
pubmed: 12236780
Bioconjug Chem. 1991 Nov-Dec;2(6):435-40
pubmed: 1805941
Front Immunol. 2017 Aug 21;8:977
pubmed: 28871254
Chem Commun (Camb). 2011 Oct 14;47(38):10752-4
pubmed: 21874179
Molecules. 2018 May 20;23(5):
pubmed: 29783774
Contrast Media Mol Imaging. 2012 Mar-Apr;7(2):254-64
pubmed: 22434639
J Nucl Med. 2015 Jul;56(7):1094-9
pubmed: 25977460
Nucl Med Biol. 2009 May;36(4):363-9
pubmed: 19423003
ChemistryOpen. 2015 Apr;4(2):174-82
pubmed: 25969816
Mol Imaging Biol. 2017 Dec;19(6):867-877
pubmed: 28409338
Chem Soc Rev. 2018 Dec 21;47(24):9106-9136
pubmed: 30259933
Mol Pharm. 2019 Aug 5;16(8):3524-3533
pubmed: 31268724
Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1718-29
pubmed: 23778558
J Nucl Med. 2019 May;60(5):587-591
pubmed: 30902878
Protein Eng Des Sel. 2014 Oct;27(10):317-24
pubmed: 25095796
Bioconjug Chem. 2011 Oct 19;22(10):1946-53
pubmed: 21863904
Br J Cancer. 1995 Oct;72(4):905-11
pubmed: 7547238
Bioconjug Chem. 2018 Nov 21;29(11):3595-3605
pubmed: 30285419
Cancer Res. 2017 Oct 1;77(19):5374-5383
pubmed: 28819024
Chembiochem. 2016 Apr 1;17(7):529-53
pubmed: 26789551
Nucl Med Biol. 2018 Jan;56:10-20
pubmed: 29031230
Nat Biotechnol. 2008 Aug;26(8):925-32
pubmed: 18641636
Cancer Res. 2000 Aug 15;60(16):4453-60
pubmed: 10969792
Curr Protoc Protein Sci. 2017 Feb 2;87:15.1.1-15.1.23
pubmed: 28150879
Annu Rev Pharmacol Toxicol. 2004;44:195-217
pubmed: 14744244
Angew Chem Int Ed Engl. 2014 Sep 26;53(40):10585-7
pubmed: 25070879
Chem Asian J. 2009 May 4;4(5):630-40
pubmed: 19235822
Mol Pharm. 2019 Jan 7;16(1):214-226
pubmed: 30427188